

Understanding the experiences of individuals with rheumatic disease during the COVID-19 pandemic

**PARTICIPATE AT: UNIFIEDCOVID.com**

Mental health





**31.9%**

Anxiety


**19.8%**

Depression

**8.8%** tested for COVID-19



**90.7%**



**7.4%**

*437 responses from participants with a rheumatic disease*

**20.6%** did not start a new prescription

**13.6%** stopped taking their medication

**10.5%** had difficulty taking their medication as prescribed



Rheumatoid arthritis	57.6%
Osteoarthritis	13.5%
Psoriatic arthritis	10.5%
Lupus	10.2%
Sjogren's Syndrome	7.5%
Ankylosing	6.3%
Juvenile idiopathic arthritis	4.9%
Connective tissue disease	4.4%
Gout	2.1%
Myositis	0.9%
Systemic sclerosis	0.9%
Vasculitis	0.9%

**Most common treatments**

DMARDs	60.8%
Methotrexate	33.6%
Chloroquine	31.2%
Hydroxychloroquine	30.1%
Biologics	39.6%